---

	Age at the time of stage IV diagnosis (in years)		Race/ethnicity	--Select-- White Black Other	Karnofsky performance status	--Select-- 90-100 70-80 10-60
	Age: missing response Age must be integer 0 to 100		Race/ethnicity: missing response		Karnofsky performance status: missing response
	Metastasis-free interval	--Select-- De novo MFI<=24 months MFI>24 months	Number of organs involved with metastasis	--Select-- 1 2 3 >=4	Organs involved with metastasis	--Select-- Bone only Non-visceral (soft tissue, lymphadenopathy, skin; can include bone) Visceral organs (lung, liver) without CNS involvement, with or without bone or non-visceral involvement CNS involvement with or without other organ or bone involvement
	Metastasis-free interval: missing response		Number of organs involved with metastasis: missing response		Organs involved with metastasis: missing response
	ER (Estrogen receptor status)	--Select-- Negative Positive Unknown	PR (Progesterone receptor status)	--Select-- Negative Positive Unknown	HER2 (Human epidermal growth factor receptor-2 status)	--Select-- Negative Positive
	Estrogen receptor status: missing response		Progesterone receptor status: missing response		Human epidermal growth factor receptor-2 status: missing response
	HR/HER2 status		Frontline hormone therapy	--Select-- No Yes Unknown	Frontline trastuzumab or pertuzumab	--Select-- No Yes Unknown
			Frontline hormone therapy: missing response		Frontline trastuzumab or pertuzumab: missing response
				ASCO Guideline for ER/PR IHC Testing		ASCO Guideline for HER2 Testing

---

This breast cancer survival prediction tool provides 5-year based on model derived from patients who underwent surgery as their 1st treatment from 1990 to 2016 at the University of Texas MD Anderson Cancer Center and received state-of the art treatment. The tool has been validated in an external dataset from the National Comprehensive Cancer Network (NCCN) database. The information provided here may be used as an aid in discussions between physicians and patients.